Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the <i>Fmr1</i>-KO Mouse Model of Fragile X Syndrome

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the <i>Fmr1</i>-KO Mouse Model of Fragile X Syndrome

Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...

Full description

Bibliographic Details
Main Authors: Marika Premoli, William Fyke, Luigi Bellocchio, Valerie Lemaire, Marie Wolley-Roberts, Bruno Bontempi, Susanna Pietropaolo
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cells
Subjects:
phytocannabinoids
<i>Fmr1</i>
mouse behavior
neurodevelopmental disorders
interleukins
neurotrophins
Online Access:https://www.mdpi.com/2073-4409/12/15/1927

Internet

https://www.mdpi.com/2073-4409/12/15/1927

Similar Items